;PMID: 10192393
;source_file_1216.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:36..113] = [t:36..113]
;2)section:[e:117..152] = [t:117..152]
;3)section:[e:156..288] = [t:156..288]
;4)sentence:[e:292..355] = [t:292..355]
;5)sentence:[e:356..528] = [t:356..528]
;6)sentence:[e:530..696] = [t:530..696]
;7)sentence:[e:697..964] = [t:697..964]
;8)sentence:[e:965..1118] = [t:965..1118]
;9)sentence:[e:1119..1368] = [t:1119..1368]
;10)sentence:[e:1369..1450] = [t:1369..1450]
;11)sentence:[e:1451..1592] = [t:1451..1592]
;12)sentence:[e:1593..1775] = [t:1593..1775]
;13)sentence:[e:1776..1995] = [t:1776..1995]
;14)section:[e:1999..2044] = [t:1999..2044]

;section 0 Span:0..31
;Nat Genet  1999 Apr;21(4):410-3
(SEC
  (FRAG (NNP:[0..3] Nat) (NNP:[4..9] Genet) (CD:[11..15] 1999)
        (.:[16..23] Apr;21-LRB-) (CD:[23..25] 4-RRB-) (CD:[25..29] :410)
        (::[29..30] -) (CD:[30..31] 3)))

;sentence 1 Span:36..113
;A common human skin tumour is caused by activating mutations in
;beta-catenin.
;[51..62]:malignancy:"skin tumour"
;[100..112]:gene-rna:"beta-catenin"
(SENT
  (S-HLN
    (NP-SBJ-1 (DT:[36..37] A) (JJ:[38..44] common) (JJ:[45..50] human)
       (NN:[51..55] skin) (NN:[56..62] tumour))
    (VP (VBZ:[63..65] is)
      (VP (VBN:[66..72] caused)
        (NP-1 (-NONE-:[72..72] *))
        (PP (IN:[73..75] by)
          (NP-LGS
            (NP (VBG:[76..86] activating) (NNS:[87..96] mutations))
            (PP (IN:[97..99] in)
              (NP (NN:[100..112] beta-catenin)))))))
    (.:[112..113] .)))

;section 2 Span:117..152
;Chan EF, Gat U, McNiff JM, Fuchs E.
(SEC
  (FRAG (NNP:[117..121] Chan) (NNP:[122..124] EF) (,:[124..125] ,)
        (NNP:[126..129] Gat) (NNP:[130..131] U) (,:[131..132] ,)
        (NNP:[133..139] McNiff) (NNP:[140..142] JM) (,:[142..143] ,)
        (NNP:[144..149] Fuchs) (NNP:[150..152] E.)))

;section 3 Span:156..288
;Howard Hughes Medical Institute, Department of Molecular Genetics and Cell 
;Biology, The University of Chicago, Illinois 60637, USA.
(SEC
  (FRAG (NNP:[156..162] Howard) (NNP:[163..169] Hughes) (NNP:[170..177] Medical)
        (NNP:[178..187] Institute) (,:[187..188] ,) (NNP:[189..199] Department)
        (IN:[200..202] of) (NNP:[203..212] Molecular) (NNP:[213..221] Genetics)
        (CC:[222..225] and) (NNP:[226..230] Cell) (NNP:[232..239] Biology)
        (,:[239..240] ,) (DT:[241..244] The) (NNP:[245..255] University)
        (IN:[256..258] of) (NNP:[259..266] Chicago) (,:[266..267] ,)
        (NNP:[268..276] Illinois) (VBD:[277..282] 60637) (NNP:[282..283] ,)
        (NNP:[284..287] USA) (.:[287..288] .)))

;sentence 4 Span:292..355
;WNT signalling orchestrates a number of developmental programs.
;[292..295]:gene-generic:"WNT"
(SENT
  (S
    (NP-SBJ (NN:[292..295] WNT) (NN:[296..306] signalling))
    (VP (VBZ:[307..319] orchestrates)
      (NP
        (NP (DT:[320..321] a) (NN:[322..328] number))
        (PP (IN:[329..331] of)
          (NP (JJ:[332..345] developmental) (NNS:[346..354] programs)))))
    (.:[354..355] .)))

;sentence 5 Span:356..528
;In response to  this stimulus, cytoplasmic beta-catenin (encoded by CTNNB1)
;is stabilized,  enabling downstream transcriptional activation by members of
;the LEF/TCF family.
;[399..411]:gene-protein:"beta-catenin"
;[424..430]:gene-rna:"CTNNB1"
;[513..516]:gene-generic:"LEF"
;[517..520]:gene-generic:"TCF"
(SENT
  (S
    (PP (IN:[356..358] In)
      (NP
        (NP (NN:[359..367] response))
        (PP (TO:[368..370] to)
          (NP (DT:[372..376] this) (NN:[377..385] stimulus)))))
    (,:[385..386] ,)
    (NP-SBJ-1 (JJ:[387..398] cytoplasmic) (NN:[399..411] beta-catenin)
      (PRN (-LRB-:[412..413] -LRB-)
        (VP (VBN:[413..420] encoded)
          (NP (-NONE-:[420..420] *))
          (PP (IN:[421..423] by)
            (NP-LGS (NN:[424..430] CTNNB1))))
        (-RRB-:[430..431] -RRB-)))
    (VP (VBZ:[432..434] is)
      (VP (VBN:[435..445] stabilized)
        (NP-1 (-NONE-:[445..445] *))
        (,:[445..446] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[446..446] *))
          (VP (VBG:[448..456] enabling)
            (NP
              (NP (JJ:[457..467] downstream) (JJ:[468..483] transcriptional)
                  (NN:[484..494] activation))
              (PP (IN:[495..497] by)
                (NP
                  (NP (NNS:[498..505] members))
                  (PP (IN:[506..508] of)
                    (NP (DT:[509..512] the)
                      (NML (NN:[513..516] LEF) (SYM:[516..517] /)
                           (NN:[517..520] TCF))
                      (NN:[521..527] family))))))))))
    (.:[527..528] .)))

;sentence 6 Span:530..696
;One of the target genes for beta-catenin/TCF encodes c-MYC, explaining why 
;constitutive activation of the WNT pathway can lead to cancer, particularly
;in  the colon.
;[558..570]:gene-protein:"beta-catenin"
;[571..574]:gene-protein:"TCF"
;[583..588]:gene-protein:"c-MYC"
;[637..640]:gene-generic:"WNT"
;[661..667]...[682..695]:malignancy:"cancer"..."in  the colon"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[530..533] One))
      (PP (IN:[534..536] of)
        (NP
          (NP (DT:[537..540] the) (NN:[541..547] target) (NNS:[548..553] genes))
          (PP (IN:[554..557] for)
            (NP (NN:[558..570] beta-catenin) (SYM:[570..571] /)
                (NN:[571..574] TCF))))))
    (VP (VBZ:[575..582] encodes)
      (NP (NN:[583..588] c-MYC))
      (,:[588..589] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[589..589] *))
        (VP (VBG:[590..600] explaining)
          (SBAR-PRP (WRB:[601..604] why)
            (S
              (NP-SBJ
                (NP (JJ:[606..618] constitutive) (NN:[619..629] activation))
                (PP (IN:[630..632] of)
                  (NP (DT:[633..636] the) (NN:[637..640] WNT)
                      (NN:[641..648] pathway))))
              (VP (MD:[649..652] can)
                (VP (VB:[653..657] lead)
                  (PP-CLR (TO:[658..660] to)
                    (NP
                      (NP (NN:[661..667] cancer))
                      (,:[667..668] ,)
                      (PP-LOC
                        (ADVP (RB:[669..681] particularly))
                        (IN:[682..684] in)
                        (NP (DT:[686..689] the) (NN:[690..695] colon))))))))))))
    (.:[695..696] .)))

;sentence 7 Span:697..964
;Most colon cancers arise from mutations in the gene encoding  adenomatous
;polyposis coli (APC), a protein required for ubiquitin-mediated  degradation
;of beta-catenin, but a small percentage of colon and some other  cancers
;harbour beta-catenin-stabilizing mutations.
;[702..715]:malignancy:"colon cancers"
;[759..785]:gene-protein:"adenomatous polyposis coli"
;[787..790]:gene-protein:"APC"
;[816..825]:gene-protein:"ubiquitin"
;[851..863]:gene-protein:"beta-catenin"
;[891..896]...[913..920]:malignancy:"colon"..."cancers"
;[929..941]:gene-generic:"beta-catenin"
(SENT
  (S
    (S
      (NP-SBJ (JJS:[697..701] Most)
         (NN:[702..707] colon) (NNS:[708..715] cancers))
      (VP (VBP:[716..721] arise)
        (PP-CLR (IN:[722..726] from)
          (NP
            (NP (NNS:[727..736] mutations))
            (PP-LOC (IN:[737..739] in)
              (NP
                (NP (DT:[740..743] the) (NN:[744..748] gene))
                (VP (VBG:[749..757] encoding)
                  (NP
                    (NP
                      (NP (JJ:[759..770] adenomatous) (NN:[771..780] polyposis)
                          (NN:[781..785] coli))
                      (NP (-LRB-:[786..787] -LRB-) (NN:[787..790] APC)
                          (-RRB-:[790..791] -RRB-)))
                    (,:[791..792] ,)
                    (NP
                      (NP (DT:[793..794] a) (NN:[795..802] protein))
                      (VP (VBN:[803..811] required)
                        (NP (-NONE-:[811..811] *))
                        (PP (IN:[812..815] for)
                          (NP
                            (NP
                              (ADJP (NN:[816..825] ubiquitin)
                                    (HYPH:[825..826] -)
                                    (VBN:[826..834] mediated))
                              (NN:[836..847] degradation))
                            (PP (IN:[848..850] of)
                              (NP (NN:[851..863] beta-catenin)))))))))))))))
    (,:[863..864] ,) (CC:[865..868] but)
    (S
      (NP-SBJ
        (NP (DT:[869..870] a) (JJ:[871..876] small) (NN:[877..887] percentage))
        (PP (IN:[888..890] of)
          (NP
            (NP (NN:[891..896] colon)
              (NML-1 (-NONE-:[896..896] *P*)))
            (CC:[897..900] and)
            (NP (DT:[901..905] some) (JJ:[906..911] other)
              (NML-1 (NNS:[913..920] cancers))))))
      (VP (VBP:[921..928] harbour)
        (NP
          (ADJP (NN:[929..941] beta-catenin) (HYPH:[941..942] -)
                (VBG:[942..953] stabilizing))
          (NNS:[954..963] mutations))))
    (.:[963..964] .)))

;sentence 8 Span:965..1118
;Recently, we discovered that  transgenic mice expressing an activated
;beta-catenin are predisposed to  developing skin tumours resembling
;pilomatricomas.
;[1035..1047]:gene-protein:"beta-catenin"
;[1079..1091]:malignancy:"skin tumours"
;[1103..1117]:malignancy:"pilomatricomas"
(SENT
  (S
    (ADVP (RB:[965..973] Recently))
    (,:[973..974] ,)
    (NP-SBJ (PRP:[975..977] we))
    (VP (VBD:[978..988] discovered)
      (SBAR (IN:[989..993] that)
        (S
          (NP-SBJ-1
            (NP (JJ:[995..1005] transgenic) (NNS:[1006..1010] mice))
            (VP (VBG:[1011..1021] expressing)
              (NP (DT:[1022..1024] an) (VBN:[1025..1034] activated)
                  (NN:[1035..1047] beta-catenin))))
          (VP (VBP:[1048..1051] are)
            (VP (VBN:[1052..1063] predisposed)
              (S
                (NP-SBJ-1 (-NONE-:[1063..1063] *))
                (VP (TO:[1064..1066] to)
                  (VP (VBG:[1068..1078] developing)
                    (NP
                      (NP (NN:[1079..1083] skin) (NNS:[1084..1091] tumours))
                      (VP (VBG:[1092..1102] resembling)
                        (NP (NNS:[1103..1117] pilomatricomas))))))))))))
    (.:[1117..1118] .)))

;sentence 9 Span:1119..1368
;Given that the skin of these  adult mice also exhibits signs of de novo
;hair-follicle morphogenesis, we  wondered whether human pilomatricomas might
;originate from hair matrix cells and  whether they might possess
;beta-catenin-stabilizing mutations.
;[1247..1261]:malignancy:"pilomatricomas"
;[1333..1345]:gene-generic:"beta-catenin"
(SENT
  (S
    (PP (VBN:[1119..1124] Given)
      (SBAR (IN:[1125..1129] that)
        (S
          (NP-SBJ
            (NP (DT:[1130..1133] the) (NN:[1134..1138] skin))
            (PP (IN:[1139..1141] of)
              (NP (DT:[1142..1147] these) (JJ:[1149..1154] adult)
                  (NNS:[1155..1159] mice))))
          (ADVP (RB:[1160..1164] also))
          (VP (VBZ:[1165..1173] exhibits)
            (NP
              (NP (NNS:[1174..1179] signs))
              (PP (IN:[1180..1182] of)
                (NP
                  (ADJP (FW:[1183..1185] de) (FW:[1186..1190] novo))
                  (NML (NN:[1191..1195] hair) (HYPH:[1195..1196] -)
                       (NN:[1196..1204] follicle))
                  (NN:[1205..1218] morphogenesis))))))))
    (,:[1218..1219] ,)
    (NP-SBJ (PRP:[1220..1222] we))
    (VP (VBD:[1224..1232] wondered)
      (SBAR
        (SBAR (IN:[1233..1240] whether)
          (S
            (NP-SBJ (JJ:[1241..1246] human) (NNS:[1247..1261] pilomatricomas))
            (VP (MD:[1262..1267] might)
              (VP (VB:[1268..1277] originate)
                (PP (IN:[1278..1282] from)
                  (NP (NN:[1283..1287] hair) (NN:[1288..1294] matrix)
                      (NNS:[1295..1300] cells)))))))
        (CC:[1301..1304] and)
        (SBAR (IN:[1306..1313] whether)
          (S
            (NP-SBJ (PRP:[1314..1318] they))
            (VP (MD:[1319..1324] might)
              (VP (VB:[1325..1332] possess)
                (NP
                  (ADJP (NN:[1333..1345] beta-catenin) (HYPH:[1345..1346] -)
                        (VBG:[1346..1357] stabilizing))
                  (NNS:[1358..1367] mutations))))))))
    (.:[1367..1368] .)))

;sentence 10 Span:1369..1450
;Here, we explore  the cell origin and aetiology of this common human skin
;tumour.
;[1438..1449]:malignancy:"skin tumour"
(SENT
  (S
    (ADVP (RB:[1369..1373] Here))
    (,:[1373..1374] ,)
    (NP-SBJ (PRP:[1375..1377] we))
    (VP (VBP:[1378..1385] explore)
      (NP
        (NP
          (NP (DT:[1387..1390] the) (NN:[1391..1395] cell)
              (NN:[1396..1402] origin))
          (CC:[1403..1406] and)
          (NP (NN:[1407..1416] aetiology)))
        (PP (IN:[1417..1419] of)
          (NP (DT:[1420..1424] this) (JJ:[1425..1431] common)
              (JJ:[1432..1437] human)
             (NN:[1438..1442] skin) (NN:[1443..1449] tumour)))))
    (.:[1449..1450] .)))

;sentence 11 Span:1451..1592
;We found nuclear  LEF-1 in the dividing tumour cells, providing biochemical
;evidence that  pilomatricomas are derived from hair matrix cells.
;[1469..1474]:gene-protein:"LEF-1"
;[1491..1503]:malignancy:"tumour cells"
;[1542..1556]:malignancy:"pilomatricomas"
(SENT
  (S
    (NP-SBJ (PRP:[1451..1453] We))
    (VP (VBD:[1454..1459] found)
      (NP (JJ:[1460..1467] nuclear) (NN:[1469..1474] LEF-1))
      (PP-LOC (IN:[1475..1477] in)
        (NP (DT:[1478..1481] the) (VBG:[1482..1490] dividing)
           (NN:[1491..1497] tumour) (NNS:[1498..1503] cells)))
      (,:[1503..1504] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1504..1504] *))
        (VP (VBG:[1505..1514] providing)
          (NP
            (NP (JJ:[1515..1526] biochemical) (NN:[1527..1535] evidence))
            (SBAR (IN:[1536..1540] that)
              (S
                (NP-SBJ-1 (NNS:[1542..1556] pilomatricomas))
                (VP (VBP:[1557..1560] are)
                  (VP (VBN:[1561..1568] derived)
                    (NP-1 (-NONE-:[1568..1568] *))
                    (PP (IN:[1569..1573] from)
                      (NP (NN:[1574..1578] hair) (NN:[1579..1585] matrix)
                          (NNS:[1586..1591] cells)))))))))))
    (.:[1591..1592] .)))

;sentence 12 Span:1593..1775
;At least 75% of these tumours  possess mutations affecting the amino-terminal
;segment, normally involved in  phosphorylation-dependent, ubiquitin-mediated
;degradation of the protein.
;[1615..1622]:malignancy:"tumours"
;[1729..1738]:gene-protein:"ubiquitin"
(SENT
  (S
    (NP-SBJ
      (NP
        (QP (IN:[1593..1595] At) (JJS:[1596..1601] least) (CD:[1602..1604] 75))
        (NN:[1604..1605] %))
      (PP (IN:[1606..1608] of)
        (NP (DT:[1609..1614] these) (NNS:[1615..1622] tumours))))
    (VP (VBP:[1624..1631] possess)
      (NP
        (NP (NNS:[1632..1641] mutations))
        (VP (VBG:[1642..1651] affecting)
          (NP
            (NP (DT:[1652..1655] the)
              (ADJP (JJ:[1656..1661] amino) (HYPH:[1661..1662] -)
                    (JJ:[1662..1670] terminal))
              (NN:[1671..1678] segment))
            (,:[1678..1679] ,)
            (VP
              (ADVP (RB:[1680..1688] normally))
              (VBN:[1689..1697] involved)
              (NP (-NONE-:[1697..1697] *))
              (PP-CLR (IN:[1698..1700] in)
                (NP
                  (NP
                    (ADJP (NN:[1702..1717] phosphorylation)
                          (HYPH:[1717..1718] -) (JJ:[1718..1727] dependent))
                    (,:[1727..1728] ,)
                    (ADJP (NN:[1729..1738] ubiquitin) (HYPH:[1738..1739] -)
                          (VBN:[1739..1747] mediated))
                    (NN:[1748..1759] degradation))
                  (PP (IN:[1760..1762] of)
                    (NP (DT:[1763..1766] the) (NN:[1767..1774] protein))))))))))
    (.:[1774..1775] .)))

;sentence 13 Span:1776..1995
;This  percentage of CTNNB1 mutations is greater than in all other human
;tumours  examined thus far, and directly implicates beta-catenin/LEF
;misregulation as the  major cause of hair matrix cell tumorigenesis in
;humans.
;[1796..1802]:gene-rna:"CTNNB1"
;[1900..1912]:gene-generic:"beta-catenin"
;[1913..1916]:gene-generic:"LEF"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1776..1780] This) (NN:[1782..1792] percentage))
      (PP (IN:[1793..1795] of)
        (NP (NN:[1796..1802] CTNNB1) (NNS:[1803..1812] mutations))))
    (VP
      (VP (VBZ:[1813..1815] is)
        (ADJP-PRD
          (ADJP (JJR:[1816..1823] greater))
          (PP (IN:[1824..1828] than)
            (PP (IN:[1829..1831] in)
              (NP
                (NP (DT:[1832..1835] all) (JJ:[1836..1841] other)
                    (JJ:[1842..1847] human) (NNS:[1848..1855] tumours))
                (VP (VBN:[1857..1865] examined)
                  (NP (-NONE-:[1865..1865] *))
                  (ADVP-TMP (RB:[1866..1870] thus) (RB:[1871..1874] far))))))))
      (,:[1874..1875] ,) (CC:[1876..1879] and)
      (VP
        (ADVP (RB:[1880..1888] directly))
        (VBZ:[1889..1899] implicates)
        (NP
          (NML (NN:[1900..1912] beta-catenin) (SYM:[1912..1913] /)
               (NN:[1913..1916] LEF))
          (NN:[1917..1930] misregulation))
        (PP (IN:[1931..1933] as)
          (NP
            (NP (DT:[1934..1937] the) (JJ:[1939..1944] major)
                (NN:[1945..1950] cause))
            (PP (IN:[1951..1953] of)
              (NP (NN:[1954..1958] hair) (NN:[1959..1965] matrix)
                  (NN:[1966..1970] cell) (NN:[1971..1984] tumorigenesis)))))
        (PP-LOC (IN:[1985..1987] in)
          (NP (NNS:[1988..1994] humans)))))
    (.:[1994..1995] .)))

;section 14 Span:1999..2044
;PMID: 10192393 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1999..2003] PMID) (::[2003..2004] :) (CD:[2005..2013] 10192393)
        (NN:[2014..2015] -LSB-) (NNP:[2015..2021] PubMed) (::[2022..2023] -)
        (NN:[2024..2031] indexed) (IN:[2032..2035] for)
        (NNP:[2036..2044] MEDLINE-RSB-)))
